Moderna says its new vaccine candidate, which fights both the original COVID-19 strain and the now-dominant omicron variant, shows a "superior neutralizing antibody response" against the coronavirus compared to its original vaccine.
The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate to have an effective booster ready for fall of 2022, the company said.
